La vendita allo scoperto per ITmedia dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ITmedia. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ITmedia (OTC:ITMAF) Azioni, Report sulle vendite allo scoperto

ITmedia Inc is a Japan-based company engages in the provision of information and services related to technology and business fields.

ITmedia Inc

Baird analyst Michael Halloran maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Neutral and raises the price target from $118 to $125.

News

Price Target

Analyst Ratings

Baird Maintains Neutral on Emerson Electric, Raises Price Target to $125

Biotech

Earnings

Guidance

Health Care

General

ACRS

Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028

BMWYY

BMW Group Q3 2024 Revenue €32.4B Vs €38.46B YoY

2024 Earnings Guidance and Outlook
<ul>
<li>Avista Corp. is lowering its 2024 consolidated earnings guidance to a range of $2.26 to $2.46 per diluted share as a result of lower-than-expected valuations at our other businesses.</li>
<li>Including the expected ERM impact of negative $0.08 per diluted share, we expect Avista Utilities to contribute near the low end of the range of $2.23 to $2.39 per diluted share in 2024.</li>
<li>We expect AEL&amp;P to contribute in the range of $0.09 to $0.11 per diluted share in 2024.</li>
<li>Valuations in the private equity markets have not recovered to the degree we expected. As a result, we now expect our other businesses to have a net loss in the range of $0.06 to $0.04 per diluted share in 2024.</li>
<li>Our guidance does not include the effect of unusual or non-recurring items until the effects are probable. Various factors could cause actual results to differ materially from our expectations, including our earnings guidance. Please refer to our 10-K for 2023, our 10-Q for the third quarter of 2024, and the cautionary statements below, for a full discussion of these factors.</li>
</ul>

Avista Corp Lowers Its 2024 Guidance: Now Sees EPS Of $2.26-$2.46 (Prior $2.36-$2.56) Vs. $2.44 Est.

Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. The company reported quarterly sales of $1.34 million which missed the analyst consensus estimate of $1.86 million by 28.03 percent. This is a 71.25 percent decrease over sales of $4.66 million the same period last year.

ABUS

Arbutus Biopharma Q3 2024 GAAP EPS $(0.10) Misses $(0.09) Estimate, Sales $1.34M Miss $1.86M Estimate

Baird analyst David Leiker maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Neutral and raises the price target from $330 to $372.

Baird Maintains Neutral on Cummins, Raises Price Target to $372

FPAY

FlexShopper Announced A Strategic Partnership With The Aftermarket Auto Parts Alliance To Expand Its Payment Solutions To Over 7,800 Locations Representing A 246% Increase From The Beginning Of 2024

Baird analyst Ghansham Panjabi maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $150 to $110.

Baird Maintains Outperform on Celanese, Lowers Price Target to $110

Barclays analyst Jiong Shao initiates coverage on Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with a Overweight rating and announces Price Target of $19.

Initiation

VIPS

Barclays Initiates Coverage On Vipshop Holdings with Overweight Rating, Announces Price Target of $19

PSTV

Plus Therapeutics And SpectronRx Announced The Signing Of A Manufacturing Services Agreement For The Production Of Rhenium (186Re) Obisbemeda, An Innovative Radiotherapy For CNS Cancers, Including Leptomeningeal Metastases And Recurrent Glioblastoma

Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(1.99) by 38.19 percent. The company reported quarterly sales of $302.000 thousand which beat the analyst consensus estimate of $296.000 thousand by 2.03 percent. This is a 35.47 percent decrease over sales of $468.000 thousand the same period last year.

Earnings Beats

Earnings Misses

PRAX

Praxis Precision Medicine Q3 2024 GAAP EPS $(2.75) Misses $(1.99) Estimate, Sales $302.000K Beat $296.000K Estimate

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

LNTH

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and raises the price target from $18 to $20.

TRDA

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Raises Price Target to $20

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.28) by 14.84 percent. The company reported quarterly sales of $58.409 million which missed the analyst consensus estimate of $58.557 million by 0.25 percent. This is a 9.75 percent decrease over sales of $64.718 million the same period last year.

EHTH

eHealth Q3 2024 Adj. EPS $(1.47) Misses $(1.28) Estimate, Sales $58.409M Miss $58.557M Estimate

For the fourth quarter of 2024, the Company expects revenues to be in the range of $58 million to $63 million and adjusted EBITDA margin between 12% to 16%.

KRNT

Kornit Digital Expects Q4 2024 Revenues Of $58M-$63M Vs. $50.468M Consensus; Sees Adjusted EBITDA Margin Of 12% to 16%

OESX

Orion Expects FY25 Revenue Growth Outlook Of Approximately 10% And Expects Second Half Revenue To Be More Weighted To The Fourth Quarter

eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) affirms FY2024 sales outlook from $470.00 million-495.00 million to $470.00 million-495.00 million.

eHealth Affirms FY2024 Sales Guidance to $470.00M-495.00M  VS Est. 483.54M

Morgan Stanley analyst Thomas Yeh maintains Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) with a Overweight and lowers the price target from $9 to $8.

LION

Morgan Stanley Maintains Overweight on Lionsgate Studios, Lowers Price Target to $8

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.41 per share. This is a 22.64 percent decrease over earnings of $0.53 per share from the same period last year. The company reported $111.92 million in sales this quarter. This is a 10.47 percent decrease over sales of $125.00 million the same period last year.

Genie Energy Q3 EPS $0.41 Down From $0.53 YoY, Sales $111.92M Down From $125.00M YoY

Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.07 by 57.14 percent. The company reported quarterly sales of $50.732 million which beat the analyst consensus estimate of $50.468 million by 0.52 percent. This is a 14.34 percent decrease over sales of $59.224 million the same period last year.

Comments

ITmedia

Vendite allo scoperto

ITmedia (OTC:ITMAF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO